CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 92 enrolled
Drug / intervention
Ergocalciferol +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00491322
NCT00491322N/ACompleted
CompareCT.gov

Impact of Vitamin D Deficiency on Insulin Resistance and the Regulation of FGF-23

Massachusetts General Hospital·interventional·Posted Jun 26, 2007·Updated May 2, 2018

In Brief

A clinical study evaluating Ergocalciferol and Ergocalciferol placebo for Vitamin D Deficiency. Completed, enrolled 92 participants across 1 site.

Detailed Summary

The purpose of this project is to determine if treating vitamin D deficiency decreases insulin resistance and improves insulin secretion in healthy volunteers. Additionally, this project will investigate if treating vitamin D deficiency affects a new phosphate-regulating hormone called FGF-23.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVitamin D Deficiency
CountriesUnited States
CollaboratorsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Timeline

N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 26, 2007
Enrollment StartMay 1, 2006
Primary CompletionFeb 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 19.0 years ago

Interventions

Ergocalciferoldietary

Ergocalciferol 50000 international units once a week for 12 weeks

Ergocalciferol placebodietary

Ergocalciferol placebo once a week for 12 weeks